Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

This study has been completed.
Information provided by:
Facet Biotech Identifier:
First received: April 22, 2005
Last updated: August 2, 2008
Last verified: August 2008